These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20553615)

  • 1. Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray.
    Möllerström E; Kovács A; Lövgren K; Nemes S; Delle U; Danielsson A; Parris T; Brennan DJ; Jirström K; Karlsson P; Helou K
    BMC Cancer; 2010 Jun; 10():296. PubMed ID: 20553615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues.
    Cao L; Sun PL; Yao M; Jia M; Gao H
    Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
    Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
    BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.
    Feeley LP; Mulligan AM; Pinnaduwage D; Bull SB; Andrulis IL
    Mod Pathol; 2014 Apr; 27(4):554-61. PubMed ID: 24051696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.
    Cubukcu E; Kanat O; Fatih Olmez O; Kabul S; Canhoroz M; Avci N; Deligonul A; Hartavi M; Cubukcu S; Olmez F; Kurt E; Evrensel T; Gokgoz S; Manavoglu O
    J BUON; 2013; 18(2):359-65. PubMed ID: 23818346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
    Alford SH; Toy K; Merajver SD; Kleer CG
    Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.
    Gilcrease MZ; Woodward WA; Nicolas MM; Corley LJ; Fuller GN; Esteva FJ; Tucker SL; Buchholz TA
    Am J Surg Pathol; 2009 May; 33(5):759-67. PubMed ID: 19252432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
    Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
    Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
    von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
    Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant expression of ezrin and HER2 predicts distant metastasis and poor prognosis of patients with salivary gland carcinomas.
    Hashimoto K; Hayashi R; Mukaigawa T; Yamazaki M; Fujii S
    Hum Pathol; 2017 May; 63():110-119. PubMed ID: 28300573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer in young women and prognosis: How important are proliferation markers?
    Fredholm H; Magnusson K; Lindström LS; Tobin NP; Lindman H; Bergh J; Holmberg L; Pontén F; Frisell J; Fredriksson I
    Eur J Cancer; 2017 Oct; 84():278-289. PubMed ID: 28844016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
    Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
    Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
    Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
    Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.
    Chen PM; Chu PY; Tung SL; Liu CY; Tsai YF; Lin YS; Wang WL; Wang YL; Lien PJ; Chao TC; Tseng LM
    Hum Pathol; 2017 Aug; 66():93-100. PubMed ID: 28603063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer.
    Zhang Y; Yao L; Zhang X; Ji H; Wang L; Sun S; Pang D
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1245-53. PubMed ID: 21691749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three molecular classifications surrogate to four immunohistochemical markers in 374 invasive breast carcinomas with long follow-up: which is better?
    Ruiz Martín J; Pérez Sánchez C; de las Heras Camino A
    Pathol Res Pract; 2013 Jun; 209(6):337-44. PubMed ID: 23582367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
    Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
    J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer.
    Baquero MT; Hanna JA; Neumeister V; Cheng H; Molinaro AM; Harris LN; Rimm DL
    Cancer; 2012 Oct; 118(19):4660-9. PubMed ID: 22359235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.